3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Small Cell Lung Carcinoma
46
Lymphoma, Large B-Cell, Diffuse
26
Precursor Cell Lymphoblastic Leukemia-Lymphoma
23
Leukemia, Myeloid, Acute
20
Lung Neoplasms
19
Burkitt Lymphoma
18
Recurrence
14
Lymphoma
14
Hodgkin Disease
14
Lymphoma, Non-Hodgkin
13
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
10
Neuroblastoma
10
Lymphoma, Mantle-Cell
10
Lymphoma, B-Cell
10
Leukemia
10
Carcinoma, Non-Small-Cell Lung
10
Medulloblastoma
8
Neoplasms, Germ Cell and Embryonal
7
Neoplasms
7
Lymphoma, Follicular
7
Multiple Myeloma
6
Lymphoma, T-Cell
6
Brain Neoplasms
6
Sarcoma, Ewing
5
Retinoblastoma
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Immunoblastic Lymphadenopathy
5
Ependymoma
5
Rhabdomyosarcoma
4
Rhabdoid Tumor
4
Interventions
atezolizumab
2
Carboplatin
2
durvalumab
1
anlotinib
1
Radiotherapy
1
Paclitaxel
1
Immunotherapy
1
Immune Checkpoint Inhibitors
1
Etoposide
1
Drug Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Cancer Extensive Stage
×
Etoposide
×
1 year
×
Clear all
NCT07227597
2026-05-28
MK-6070-003
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
170 enrolled